Incidence of renal injury following chemotherapy in malignant tumor patients and analysis of associated factors.

Objective: To systematically investigate the clinical characteristics, peri-chemotherapy changes in renal function, and independent risk factors associated with chemotherapy-related renal injury (CRI) in patients with malignant tumors, providing scientific basis for developing individualized prevention and intervention strategies. Methods: A retrospective study design was adopted. A total of 152 patients with malignant tumors who underwent chemotherapy in the Department of Oncology of our hospital from January 2020 to December 2023 were included. Patients were categorized into a chemotherapy-related renal injury (CRI) group ( Results: Among 152 patients undergoing chemotherapy for malignant tumors, the CRI incidence was 18.42% (28/152). The CRI group had a significantly higher proportion of patients aged ≥ 60 years, as well as higher rates of hypertension, diabetes, chronic kidney disease, use of nephrotoxic agents, and receipt of ≥ 3 chemotherapy drugs. in the CRI group than in the non-CRI group (all Conclusion: This study identifies a relatively high incidence of CRI among patients with malignant tumors undergoing chemotherapy. The findings suggest that age ≥ 60 years, diabetes, chronic kidney disease, use of nephrotoxic agents, and an increased number of chemotherapy drugs are associated with higher risk of CRI. However, due to the retrospective design and limited number of CRI events, these findings should be interpreted with caution. Further prospective studies with larger sample sizes are needed to validate these associations. These associations highlight the need for enhanced renal function monitoring and cautious selection of chemotherapy regimens, particularly in high-risk populations.